77 related articles for article (PubMed ID: 20425685)
1. Sonochemotherapy inhibits the adhesion, migration and invasion of human ovarian cancer cells with highly metastatic potential.
Zhou S; Yu T; Zhang J; Liu S; Huo Y; Zhang Y
Ultraschall Med; 2011 Jan; 32 Suppl 1():S14-20. PubMed ID: 20425685
[TBL] [Abstract][Full Text] [Related]
2. The interaction between a drug and ultrasound in sonochemotherapy against ovarian cancers.
He H; Yu T; Zhang Y
Ultraschall Med; 2012 Jun; 33(3):275-82. PubMed ID: 21165815
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
[TBL] [Abstract][Full Text] [Related]
4. Arsenic trioxide (As(2)O(3)) inhibits peritoneal invasion of ovarian carcinoma cells in vitro and in vivo.
Zhang J; Wang B
Gynecol Oncol; 2006 Oct; 103(1):199-206. PubMed ID: 16624393
[TBL] [Abstract][Full Text] [Related]
5. [Inhibitory effect of cantharidin on invasion and metastasis of highly metastatic ovarian carcinoma cell line HO-8910PM].
He TP; Mo LE; Liang NC
Ai Zheng; 2005 Apr; 24(4):443-7. PubMed ID: 15820067
[TBL] [Abstract][Full Text] [Related]
6. Treatment with paclitaxel alone rather than combination with paclitaxel and cisplatin may be selective for cisplatin-resistant ovarian carcinoma.
Yamamoto K; Kikuchi Y; Kudoh K; Hirata J; Kita T; Nagata I
Jpn J Clin Oncol; 2000 Oct; 30(10):446-9. PubMed ID: 11185891
[TBL] [Abstract][Full Text] [Related]
7. Dexamethasone enhances cell resistance to chemotherapy by increasing adhesion to extracellular matrix in human ovarian cancer cells.
Chen YX; Wang Y; Fu CC; Diao F; Song LN; Li ZB; Yang R; Lu J
Endocr Relat Cancer; 2010 Mar; 17(1):39-50. PubMed ID: 19776289
[TBL] [Abstract][Full Text] [Related]
8. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel (Taxol(R)) inhibits motility of paclitaxel-resistant human ovarian carcinoma cells.
Belotti D; Rieppi M; Nicoletti MI; Casazza AM; Fojo T; Taraboletti G; Giavazzi R
Clin Cancer Res; 1996 Oct; 2(10):1725-30. PubMed ID: 9816123
[TBL] [Abstract][Full Text] [Related]
10. Apigenin inhibited migration and invasion of human ovarian cancer A2780 cells through focal adhesion kinase.
Hu XW; Meng D; Fang J
Carcinogenesis; 2008 Dec; 29(12):2369-76. PubMed ID: 18974065
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Natali PG; Bagnato A
Can J Physiol Pharmacol; 2010 Jun; 88(6):676-81. PubMed ID: 20628434
[TBL] [Abstract][Full Text] [Related]
12. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
[TBL] [Abstract][Full Text] [Related]
13. Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells.
Taylor-Harding B; Orsulic S; Karlan BY; Li AJ
Gynecol Oncol; 2010 Dec; 119(3):549-56. PubMed ID: 20837358
[TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
Sonnemann J; Gänge J; Pilz S; Stötzer C; Ohlinger R; Belau A; Lorenz G; Beck JF
BMC Cancer; 2006 Jul; 6():183. PubMed ID: 16834771
[TBL] [Abstract][Full Text] [Related]
15. Interactions of doxycycline with chemotherapeutic agents in human breast adenocarcinoma MDA-MB-231 cells.
Foroodi F; Duivenvoorden WC; Singh G
Anticancer Drugs; 2009 Feb; 20(2):115-22. PubMed ID: 19209028
[TBL] [Abstract][Full Text] [Related]
16. Periostin promotes ovarian cancer angiogenesis and metastasis.
Zhu M; Fejzo MS; Anderson L; Dering J; Ginther C; Ramos L; Gasson JC; Karlan BY; Slamon DJ
Gynecol Oncol; 2010 Nov; 119(2):337-44. PubMed ID: 20688362
[TBL] [Abstract][Full Text] [Related]
17. Induction of p53 and drug resistance following treatment with cisplatin or paclitaxel in ovarian cancer cell lines.
Metzinger DS; Taylor DD; Gercel-Taylor C
Cancer Lett; 2006 May; 236(2):302-8. PubMed ID: 15990222
[TBL] [Abstract][Full Text] [Related]
18. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
[TBL] [Abstract][Full Text] [Related]
19. Inositol hexaphosphate (IP6) inhibits key events of cancer metastasis: I. In vitro studies of adhesion, migration and invasion of MDA-MB 231 human breast cancer cells.
Tantivejkul K; Vucenik I; Shamsuddin AM
Anticancer Res; 2003; 23(5A):3671-9. PubMed ID: 14666663
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity of drug resistance in human breast and ovarian cancers.
Kern DH
Cancer J Sci Am; 1998; 4(1):41-5. PubMed ID: 9467045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
